Sunday, July 10, 2016

NS5A RESISTANCE LEADING TO FAILURE OF 24-WEEK THERAPY WITH SOFOSBUVIR/LEDIPASVIR AND RIBAVIRIN FOR THE TREATMENT OF HEPATITIS C GENOTYPE 1A INFECTION IN A HIV-1 CO-INFECTED PATIENT

Abstract

Herein we report a previously undescribed case of treatment-emergent non-structural protein 5A (NS5A) resistance mutations, Q30H and Y93C, leading to a failure of 24-week course of sofosbuvir/ledipasvir + ribavirin therapy for the treatment of hepatitis C virus (HCV) genotype 1a in interferon-experienced, human immunodeficiency virus type 1 (HIV-1) co-infected patient with cirrhosis.

No comments:

Post a Comment